DNA_NN
methylation_NN
changes_NNS
in_IN
hematologic_JJ
malignancies_NNS
:_:
biologic_JJ
and_CC
clinical_JJ
implications_NNS
._.

DNA_NN
methylation_NN
changes_NNS
are_VBP
among_IN
the_DT
most_RBS
common_JJ
detectable_JJ
abnormalities_NNS
in_IN
human_JJ
neoplasia_NN
._.

Hypermethylation_NN
within_IN
the_DT
promoters_NNS
of_IN
selected_VBN
genes_NNS
appears_VBZ
to_TO
be_VB
especially_RB
common_JJ
in_IN
all_DT
types_NNS
of_IN
human_JJ
hematopoietic_JJ
neoplasms_NNS
,_,
and_CC
is_VBZ
usually_RB
associated_VBN
with_IN
inactivation_NN
of_IN
the_DT
involved_VBN
gene_NN
-LRB-_-LRB-
s_NNS
-RRB-_-RRB-
._.

Such_JJ
hypermethylation-associated_JJ
silencing_NN
of_IN
gene_NN
expression_NN
has_VBZ
been_VBN
shown_VBN
for_IN
several_JJ
genes_NNS
regulating_VBG
the_DT
growth_NN
and_CC
differentiation_NN
of_IN
hematopoietic_JJ
cells_NNS
,_,
including_VBG
the_DT
estrogen_NN
receptor_NN
-LRB-_-LRB-
ER_NN
-RRB-_-RRB-
gene_NN
,_,
P15_NN
,_,
P16_NN
and_CC
others_NNS
._.

Hypermethylation_NN
within_IN
the_DT
promoters_NNS
of_IN
some_DT
genes_NNS
appear_VBP
to_TO
be_VB
an_DT
early_JJ
event_NN
in_IN
the_DT
pathogenesis_NN
of_IN
neoplasia_NN
-LRB-_-LRB-
ER_NN
,_,
P15_NN
-RRB-_-RRB-
,_,
while_IN
other_JJ
genes_NNS
seem_VBP
to_TO
become_VB
methylated_VBN
during_IN
the_DT
progression_NN
of_IN
leukemias_NNS
-LRB-_-LRB-
HIC1_NN
,_,
c-abl_NN
-RRB-_-RRB-
._.

The_DT
high_JJ
prevalence_NN
of_IN
promoter_NN
methylation_NN
suggests_VBZ
that_IN
this_DT
molecular_JJ
abnormality_NN
can_MD
be_VB
used_VBN
to_TO
monitor_VB
disease_NN
activity_NN
during_IN
therapy_NN
._.

In_IN
addition_NN
,_,
new_JJ
technology_NN
allows_VBZ
the_DT
sensitive_JJ
identification_NN
of_IN
gene_NN
hypermethylation_NN
in_IN
a_DT
background_NN
of_IN
normal_JJ
cells_NNS
,_,
suggesting_VBG
possible_JJ
new_JJ
strategies_NNS
for_IN
the_DT
detection_NN
of_IN
minimal_JJ
residual_JJ
disease_NN
._.

Finally_RB
,_,
reactivation_NN
of_IN
tumor-suppressor_JJ
gene_NN
expression_NN
through_IN
pharmacologic_JJ
inhibition_NN
of_IN
DNA_NN
methyltransferase_NN
and_CC
resultant_JJ
DNA_NN
demethylation_NN
appears_VBZ
to_TO
be_VB
a_DT
promising_JJ
new_JJ
avenue_NN
of_IN
therapy_NN
in_IN
acute_JJ
leukemia_NN
._.

